Loading
Loading
Research Overview
Single-molecule dual GLP-1R and amylin receptor co-agonist; integrates GLP-1-mediated appetite suppression and insulin sensitisation with amylin-mediated brainstem and hypothalamic satiety signalling in a single molecular entity.
Amycretin combines GLP-1 receptor agonism and amylin receptor agonism (AMY1-3) within a single molecular scaffold, eliminating the need for separate semaglutide and cagrilintide injections. The compound is under investigation in both subcutaneous (once-weekly) and oral (once-daily) formulations, with Phase 1/2 data providing early evidence for efficacy and tolerability.
The dual mechanism engages two complementary appetite-suppression pathways: GLP-1 receptor-mediated reduction of food intake and delayed gastric emptying, combined with amylin receptor-mediated satiety signalling in the brainstem and hypothalamus. Early trial data from the CagriSema programme (separate cagrilintide + semaglutide injection) has demonstrated approximately 25% weight loss with dual activation — amycretin aims to deliver comparable efficacy in a single agent.
Amycretin's early Phase 1/2 weight-loss data has been notable, with dose-escalation studies reporting weight reductions that appear to exceed semaglutide monotherapy benchmarks — consistent with the additive effect hypothesis from the CagriSema data. GI tolerability was reportedly milder than semaglutide alone, potentially enabling higher combined doses.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, amycretin has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Amycretin research is most relevant to protocols examining:
Single-molecule dual GLP-1/amylin co-agonism research
Novo Nordisk pipeline next-generation obesity studies
Research comparing single-molecule vs combination (CagriSema) approaches
Oral GLP-1/amylin bioavailability investigations
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: ~5–7 days). Review data, confirm baseline recovery before any repeat protocol.
Single-molecule dual GLP-1R and amylin receptor co-agonist; integrates GLP-1-mediated appetite suppression and insulin sensitisation with amylin-mediated brainstem and hypothalamic satiety signalling in a single molecular entity.
| Parameter | Value |
|---|---|
| Dose range | Under investigation (up to 20 mg/week subcutaneous in trials) |
| Schedule | Once weekly (sub-q) or once daily (oral) |
| Route | Subcutaneous, Oral (under investigation) |
| Half-life | ~5–7 days |
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.